HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

MT-103 antibody

a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma
Also Known As:
antibody MT-103; blinatumomab
Networked: 60 relevant articles (12 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Zugmaier, Gerhard: 10 articles (12/2015 - 08/2008)
2. Nagorsen, Dirk: 9 articles (01/2015 - 06/2009)
3. Baeuerle, Patrick A: 9 articles (06/2013 - 08/2008)
4. Kufer, Peter: 7 articles (12/2012 - 08/2008)
5. Viardot, Andreas: 6 articles (12/2015 - 08/2008)
6. Klinger, Matthias: 6 articles (12/2015 - 08/2008)
7. Bargou, Ralf C: 6 articles (12/2015 - 03/2009)
8. Einsele, Hermann: 5 articles (12/2015 - 08/2008)
9. Stelljes, Matthias: 5 articles (12/2015 - 06/2011)
10. Topp, Max S: 5 articles (12/2015 - 06/2011)

Related Diseases

1. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
2. Residual Neoplasm
3. Neoplasms (Cancer)
4. Bites and Stings (Sting)
5. Lymphoma (Lymphomas)

Related Drugs and Biologics

1. Single-Chain Antibodies
2. Hydrocodone (Dihydrocodeinone)
3. type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil)
4. Antigen Receptors (Antigen Receptor)
5. Antibodies
6. rituximab (Mabthera)
7. CD19 Antigens
8. Immunotoxins (Immunotoxin)
9. Immunoconjugates (Immunoconjugate)
10. Vincristine (Oncovin)

Related Therapies and Procedures

1. Transplants (Transplant)
2. Hematopoietic Stem Cell Transplantation
3. Immunotherapy
4. Drug Therapy (Chemotherapy)
5. Immunomodulation